Research graph
References from Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET -Negative, HRAS -, and NF1 -Mutated Metastatic Medullary Thyroid Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1089/thy.2014.0335
10.1089/thy.2014.0335 · External reference
10.1016/j.isci.2019.09.030
10.1016/j.isci.2019.09.030 · External reference
10.1038/nrendo.2016.11
10.1038/nrendo.2016.11 · External reference
10.1210/jc.2012-2092
10.1210/jc.2012-2092 · External reference
10.1210/jc.2010-1921
10.1210/jc.2010-1921 · External reference
10.1210/jendso/bvae048
10.1210/jendso/bvae048 · External reference
10.1056/nejmoa2309719
10.1056/nejmoa2309719 · External reference
10.1016/s2213-8587(21)00120-0
10.1016/s2213-8587(21)00120-0 · External reference
10.1056/nejmoa2005651
10.1056/nejmoa2005651 · External reference
Unresolved reference
2025 · External reference
10.1136/jmedgenet-2016-103833
10.1136/jmedgenet-2016-103833 · External reference
10.18632/oncotarget.23986
10.18632/oncotarget.23986 · External reference
10.1089/thy.2023.0279
10.1089/thy.2023.0279 · External reference
10.1158/0008-5472.can-06-4605
10.1158/0008-5472.can-06-4605 · External reference
10.1038/s41467-019-09374-9
10.1038/s41467-019-09374-9 · External reference
10.1016/j.cellsig.2014.03.032
10.1016/j.cellsig.2014.03.032 · External reference
10.1210/jendso/bvae059
10.1210/jendso/bvae059 · External reference
10.1093/ejendo/lvad051
10.1093/ejendo/lvad051 · External reference
10.1038/labinvest.2016.142
10.1038/labinvest.2016.142 · External reference
10.3390/cancers16010031
10.3390/cancers16010031 · External reference
